

1 Policy impact evaluation: A potential use case for  
2 longitudinal monitoring of viruses in wastewater at  
3 small geographic scales

4 Elana M. G. Chan<sup>1</sup>, Amanda Bidwell<sup>1</sup>, Zongxi Li<sup>1,2</sup>, Sebastien Tilmans<sup>1,2</sup>, Alexandria B. Boehm<sup>1\*</sup>

5 <sup>1</sup> *Department of Civil and Environmental Engineering, Stanford University, Stanford, California*  
6 *94305, United States*

7 <sup>2</sup> *Codiga Resource Recovery Center, Stanford University, Stanford, California 94305, United*  
8 *State*

9 \* Corresponding author: [aboehm@stanford.edu](mailto:aboehm@stanford.edu)

10 Keywords: Wastewater-based epidemiology, SARS-CoV-2, COVID-19, Quasi-experiment,  
11 Difference-in-differences, Policy evaluation, Causal inference

## 12 Abstract

13 We used wastewater monitoring data to evaluate the impact of public health policies and  
14 interventions on the spread of COVID-19 among a university population. We first evaluated the  
15 correlation between incident, reported COVID-19 cases and wastewater SARS-CoV-2 RNA  
16 concentrations and observed changes to the correlation over time. Using a difference-in-  
17 differences approach, we evaluated the association between university COVID-19 policy  
18 changes and levels of SARS-CoV-2 RNA concentrations in wastewater. Policy changes  
19 associated with a significant change in campus wastewater SARS-CoV-2 RNA concentrations  
20 included changes to face covering recommendations, indoor gathering bans, and routine  
21 surveillance testing requirements and availability. We did not observe changes in SARS-CoV-2  
22 RNA concentrations associated with other policy changes. The work presented herein  
23 demonstrates how longitudinal wastewater monitoring of viruses may be used for causal  
24 inference such as policy impact evaluation, especially at small geographic scales.

25

## 26 1.0 Introduction

27 Nonpharmaceutical interventions (NPIs) are actions that aim to reduce the spread of an  
28 infectious disease in a community—especially when the community has little immunity to the  
29 pathogen or a vaccine is not yet available.<sup>1</sup> Examples of NPIs implemented widely in the United  
30 States at the start of the coronavirus disease 2019 (COVID-19) pandemic include face mask  
31 mandates, stay-at-home orders, non-essential business closures, and large gathering bans.<sup>2</sup>  
32 Although the implementation of NPIs intended to benefit communities by flattening the epidemic  
33 curve—that is by reducing the peak number of cases and burden on the health care system—  
34 the implementation of NPIs also led to negative economic consequences and tolls on social  
35 well-being.<sup>3–5</sup> Governments and institutional leadership are tasked with balancing public health,  
36 social well-being, and economic prospects in the face of epidemics. Evidence-based knowledge  
37 can help policymakers and leaders make better-informed decisions in dire situations.

38 Following the initial wave of the pandemic, several studies empirically assessed the impact of  
39 NPIs on health-related outcomes. The findings of these studies suggest that NPIs reduced the  
40 spread of severe acute respiratory disease syndrome coronavirus 2 (SARS-CoV-2) virus, with  
41 school and workplace closures, business restrictions, large gathering bans, and mask mandates  
42 among the most impactful NPIs.<sup>6–10</sup> A review of the various methodologies used by these  
43 studies found that around half analyzed raw outcome data and half analyzed computed  
44 outcome data (i.e., raw outcome data was used to compute another outcome).<sup>11</sup> The most  
45 common raw outcomes analyzed were clinical surveillance reports (e.g., confirmed cases or  
46 deaths) and human mobility (e.g., tracking of mobile phones).<sup>11</sup> The most common computed  
47 outcomes analyzed were COVID-19 growth rate and effective reproduction number.<sup>11</sup>

48 Although clinical surveillance and mobile phone tracking are the most common sources of data  
49 used to evaluate NPIs, these data are not without biases and limitations. Counts of confirmed  
50 cases depend on clinical testing capacity and clinical testing rates, and deaths that occur  
51 outside of hospitals may be underreported.<sup>6–8,10,11</sup> Furthermore, clinical testing behaviors have  
52 drastically changed with the availability of self-administered antigen tests which are not reported  
53 to health departments.<sup>12</sup> Although mobility data through tracking of mobile phones is unaffected  
54 by changes in clinical testing, these data are biased towards individuals who opt into location  
55 history sharing and may not be a reliable proxy for SARS-CoV-2 transmission dynamics.<sup>13,14</sup>  
56 Wastewater monitoring, which has gained heightened attention since the start of the COVID-19  
57 pandemic, is a promising data source because it does not suffer some of the limitations of  
58 clinical surveillance and mobility data for epidemiological inference.

59 Wastewater monitoring refers to analyzing a sample of wastewater, which represents a pooled  
60 biological sample of the contributing population, for concentrations of infectious disease  
61 markers. Wastewater monitoring data capture contributions from both symptomatic and  
62 asymptomatic individuals and are not influenced by clinical testing availability or clinical test-  
63 seeking behaviors.<sup>15</sup> Studies have reported that concentrations of SARS-CoV-2 RNA in  
64 wastewater solids are correlated with laboratory-confirmed incident COVID-19 cases—although  
65 this correlation has changed since the widespread availability of self-administered antigen  
66 tests.<sup>16–19</sup> Several studies also demonstrated that wastewater monitoring can be used at  
67 geographic scales smaller than a sewershed (i.e., the population serviced by a wastewater  
68 treatment plant) to gain insight about COVID-19 incidence.<sup>20–32</sup> A potential use case for  
69 wastewater monitoring at subsewershed scales is to assess public health policies.

70 The World Health Organization particularly suggests sampling at finer spatial scales when using  
71 wastewater monitoring data to inform targeted control interventions.<sup>15</sup> Previous studies

72 evaluating NPIs using clinical surveillance or mobility data were mostly conducted at national or  
73 subnational scales, and few of these studies investigated variation in the impact of NPIs on  
74 health-related outcomes among subpopulations.<sup>11</sup> NPIs may be more or less impactful in a  
75 specific subpopulation compared to the general population (e.g., due to different interaction  
76 patterns) or public health goals may differ among subpopulations (e.g., universities aim to  
77 maximize on-campus activity).<sup>33</sup> Wastewater monitoring data may be well-suited to objectively  
78 assess NPIs, particularly among subpopulations and despite low clinical testing rates.

79 In this study, we evaluate the potential use case of wastewater monitoring data to empirically  
80 assess the impact of NPIs on the spread of COVID-19 among a university population. We begin  
81 by assessing the correlation between wastewater concentrations of SARS-CoV-2 RNA and  
82 incident, reported COVID-19 cases at Stanford University and evaluate changes to this  
83 correlation over time. Next, we evaluate the association between policies implemented at  
84 Stanford University and changes in wastewater concentrations of SARS-CoV-2 RNA using a  
85 difference-in-differences (DiD) approach. DiD is a quasi-experimental design commonly used in  
86 econometrics—although it was first used in 1854 by John Snow for epidemiologic purposes—  
87 that aims to assess the impact of an intervention on an outcome but without the use of  
88 randomization.<sup>34–36</sup> DiD designs have been used by several previous studies to evaluate the  
89 causal effects of COVID-19 policies on clinical or mobility outcomes.<sup>37–44</sup>

## 90 2.0 Methods

91 We used wastewater SARS-CoV-2 RNA monitoring data, COVID-19 case surveillance data,  
92 and dates associated with changes to campus COVID-19 policies. All calculations and statistical  
93 analyses were conducted in R (version 4.1.3). This study is approved by the Stanford  
94 Institutional Review Board (IRB) for human subject research (IRB-59746).

## 95 2.1 Wastewater monitoring data

96 We used wastewater monitoring data from the Codiga Resource Recovery Center (CR2C) and  
97 the Palo Alto Regional Water Quality Control Plant (RWQCP) for this analysis. CR2C is a pilot  
98 scale wastewater treatment facility that services a portion of the Stanford University campus  
99 (California, USA) including academic buildings and student and faculty housing (Figure S1 in  
100 the Supporting Information (SI)).<sup>45,46</sup> CR2C services approximately 10,000 people with an  
101 estimated daily flow of approximately 0.5 million gallons of wastewater each day.<sup>20,46</sup> CR2C is a  
102 subwatershed of the watershed serviced by RWQCP which is operated by the City of Palo Alto  
103 (California, USA). RWQCP services approximately 236,000 people and treats approximately 20  
104 million gallons of wastewater each day for Los Altos, Los Altos Hills, Mountain View, Palo Alto,  
105 Stanford University, and the East Palo Alto Sanitary District (Figure S1 in the SI).<sup>47</sup>

106 Prospective, longitudinal wastewater sampling from CR2C and RWQCP began July 2021 and  
107 October 2020, respectively, and is currently ongoing. Six samples per week are collected from  
108 CR2C; seven samples per week are collected from RWQCP. Sampling from CR2C was  
109 temporarily reduced to two samples per week between 1 November 2022 and 31 December  
110 2022. Details about sampling and processing methods, including quality assurance and quality  
111 control metrics, are registered in protocols.io<sup>48–50</sup> and have been described previously by Wolfe  
112 et al.<sup>51</sup> and Boehm et al.<sup>52</sup> A brief description is provided in the SI (Text S1).

113 For this analysis, we used concentrations of the SARS-CoV-2 RNA N gene in wastewater  
114 settled solids in gene copies (gc) per gram (g) dry weight (gc/g), both unnormalized (N) and  
115 normalized by pepper mild mottle virus (PMMoV) RNA concentrations in wastewater settled  
116 solids in gc/g (N/PMMoV). The N gene target is located near the frequently used N2 assay  
117 target,<sup>53</sup> and we have confirmed no mutation in the target over the course of the pandemic.<sup>19</sup>

118 PMMoV is a commonly used marker of wastewater fecal strength, and based on a mass  
119 balance model N/PMMoV should scale with disease incidence rate.<sup>18,54,55</sup> We used data  
120 between 29 July 2021 and 9 August 2023 (CR2C: 590 days; RWQCP: 736 days). The  
121 measured N gene concentration was below the limit of detection (approximately 1,000 gc/g) in  
122 29 samples from CR2C. No samples from RWQCP were below the limit of detection. We  
123 imputed half the limit of detection (500 gc/g) for the N gene concentration for samples below the  
124 limit of detection. There were no non-detects for PMMoV in the dataset. Data from RWQCP  
125 between 16 November 2020 and 31 December 2022 have been published previously by Boehm  
126 et al.<sup>52</sup> and are publicly available through the Stanford Digital Repository  
127 (<https://doi.org/10.25740/cx529np1130>).<sup>56</sup> Data from CR2C have not yet been published. All  
128 wastewater monitoring data used in this study are publicly available through the Stanford Digital  
129 Repository (<https://doi.org/10.25740/ch598gf0783>).<sup>57</sup>

## 130 2.2 COVID-19 case surveillance data

131 Reported COVID-19 cases from student-reported, self-administered antigen tests and  
132 laboratory-based PCR tests among students residing in the CR2C subwatershed are available  
133 from Stanford University. We used case data between 29 July 2021 and 9 August 2023 for this  
134 analysis. Additional details of these daily case counts are provided in the SI (Text S2).

## 135 2.3 Campus COVID-19 policies

136 Dates and details of changes to Stanford University's COVID-19 policies were obtained from  
137 Stanford COVID-19 Health Alerts.<sup>58</sup> There were 15 unique dates on which campus COVID-19  
138 policies changed (Table 1) during the study period. We categorized policies into three groups:  
139 masking (i.e., those involving the use of face coverings), mobility (i.e., those involving

140 movement or gathering of individuals), and testing (i.e., those relating to laboratory-based  
 141 surveillance testing). We further differentiated policies between those that enforced rules (i.e.,  
 142 restrictions) and those that relaxed existing rules (i.e., relaxations). More information about each  
 143 policy is included in the SI (Table S1).

144 Table 1. Changes to COVID-19 policies at Stanford University since regular wastewater sampling began  
 145 at the Codiga Resource Recovery Center

<b>Date</b>	<b>Category</b>	<b>Type</b>	<b>Policy</b>
8/3/2021	Masking	Restriction	Face coverings required indoors
9/2/2021	Masking; Mobility	Restriction; Restriction	Face coverings recommended outdoors in crowded settings; Indoor student parties prohibited
9/20/2021	Testing; Mobility	Restriction; Relaxation	Surveillance testing required for faculty, staff, and postdoctoral scholars regardless of vaccination status; Revised travel guidelines in effect
10/8/2021	Mobility	Relaxation	Indoor student parties can resume
1/3/2022	Mobility	Restriction	Online classes start
1/5/2022	Mobility; Mobility	Restriction; Restriction	No indoor events and gatherings; Outdoor-only gatherings and meetings prohibited
1/18/2022	Mobility	Relaxation	In-person instruction resumes
1/21/2022	Mobility	Relaxation	Outdoor-only gatherings and meetings allowed again
1/28/2022	Mobility	Relaxation	Indoor events and gatherings can resume
3/2/2022	Masking	Relaxation	Face coverings strongly recommended, regardless of vaccination status
4/7/2022	Testing	Relaxation	Surveillance testing no longer required for students
10/24/2022	Masking	Relaxation	Masks no longer required in classrooms and on campus shuttles
1/6/2023	Masking	Restriction	Face coverings strongly recommended indoors and in crowded outdoor settings
3/24/2023	Testing	Relaxation	Optional, free, laboratory-based PCR testing ends for employees
6/18/2023	Testing	Relaxation	Optional, free, laboratory-based PCR testing ends for students



## 146 2.4 Correlation analysis

147 Incident COVID-19 cases within the CR2C subwatershed were reported daily while between 2–  
148 6 wastewater samples per week were collected and analyzed from CR2C during the analysis  
149 period. Clinical case surveillance data may contain reporting biases on weekends. To compare  
150 the two time series, we calculated weekly average N concentrations, N/PMMoV concentrations,  
151 and incident COVID-19 cases for each epidemiological week (i.e., Sunday through Saturday).  
152 Neither raw nor  $\log_{10}$ -transformed weekly average N or N/PMMoV concentrations from CR2C  
153 are normally distributed (Shapiro-Wilk normality test,  $p < 0.01$ ), so we used Kendall's tau  
154 correlation to test the null hypothesis that weekly average wastewater SARS-CoV-2 RNA  
155 concentrations and weekly average incident COVID-19 cases in the CR2C subwatershed are  
156 not temporally correlated. We tested this null hypothesis using both unnormalized (N) and  
157 normalized (N/PMMoV) wastewater concentrations. We used the KendallTauB function from the  
158 DescTools R package to compute the 95% confidence interval for each tau estimate.<sup>59</sup>

159 We further conducted three subgroup correlation analyses. First, we grouped the data by  
160 whether wastewater sample or clinical specimen collection occurred during the academic year  
161 (autumn, winter, or spring quarter) or nonacademic year (summer quarter). We used the date  
162 halfway between the last day of classes of the previous quarter and first day of classes of the  
163 following quarter to define the start and end of quarters.<sup>60</sup> Second, we grouped the data by  
164 whether wastewater sample or clinical specimen collection occurred before or after the  
165 requirement for laboratory-based surveillance testing was suspended for vaccinated and  
166 boosted students (7 April 2022) (Table 1). The laboratory-based surveillance testing program  
167 required fully vaccinated students to test once a week (twice a week for unvaccinated students)  
168 and therefore intended to capture both symptomatic and asymptomatic cases through routine  
169 testing. Third, we grouped the data by whether wastewater sample or clinical specimen

170 collection occurred before or after 1 May 2022.<sup>19</sup> This date represents a point in time when self-  
171 administered COVID-19 antigen tests, the results of which are not reportable to health  
172 departments, were widely available.<sup>12,19</sup> For each subgroup, we grouped weekly average  
173 wastewater concentrations and incident case counts based on the end date of the  
174 epidemiological week. In total, we conducted 14 correlation analyses using subsets of the same  
175 sets of data to test the same null hypothesis, so we used an alpha value of  $0.05 / 14 = 0.004$  to  
176 account for multiple hypothesis testing when interpreting the p value associated with each tau  
177 estimate.

## 178 2.5 Policy impact evaluation

179 We used PMMoV-normalized wastewater concentrations for the remainder of the analysis as  
180 the correlation between incident COVID-19 cases and wastewater SARS-CoV-2 RNA  
181 concentrations were similar using N and N/PMMoV, and a mass balance model suggests the  
182 N/PMMoV ratio should scale with incidence rate.<sup>55</sup> To assess the association between campus  
183 COVID-19 policies and changes in N/PMMoV measurements at CR2C, we used a difference-in-  
184 differences (DiD) approach. For the DiD design, we assumed that policies went into effect at  
185 midnight on the date of implementation (day = 0). We defined the pre-treatment period as the 14  
186 days before a policy was implemented (days -14 to -1) and the post-treatment period as the 14  
187 days after a policy was implemented (days 0 to 13). We chose 14 days because 14 days is the  
188 maximum incubation period for SARS-CoV-2 and people who shed SARS-CoV-2 RNA typically  
189 do so at the start of infection.<sup>61-65</sup> We assumed that the RWQCP sewershed represents a  
190 reasonable comparison group for the CR2C subsewershed. With the exception of the East Palo  
191 Alto Sanitary District, RWQCP services cities in Santa Clara County which is the same county  
192 that Stanford University is located in. Santa Clara County entered the least restrictive “Yellow  
193 Tier” of California’s Blueprint for a Safer Economy on 19 May 2021, which lifted most local

194 orders.<sup>66</sup> Moreover, California met the criteria under the Blueprint for a Safer Economy to fully  
195 reopen the economy on 15 June 2021.<sup>67</sup> Regular sampling began at CR2C on 29 July 2021;  
196 therefore, we assumed that policies implemented by Stanford University thereafter (Table 1)  
197 were only applicable to the CR2C subsewershed population and not the greater RWQCP  
198 sewershed population. The two exceptions were 3 August 2021 and 2 March 2022 because  
199 Santa Clara County also issued the same policies (Table 1).<sup>68,69</sup> Further justification for using  
200 RWQCP as a comparison group is included in the SI (Text S3).

201 We used a regression model to implement our DiD approach (Equation 1).<sup>70</sup> A value of 0 for  
202 *time* represents the pre-treatment period (days -14 to -1) and a value of 1 represents the post-  
203 treatment period (days 0 to 13). A value of 0 for *treated* represents the untreated group  
204 (RWQCP) and a value of 1 represents the treated group (CR2C). The coefficient of the  
205 interaction between *time* and *treated* ( $\beta_3$ ) represents the DiD estimator, or the average  
206 treatment effect on the treated (ATT).<sup>35,70</sup> In this study, a positive ATT value suggests that a  
207 policy was associated with an increase in wastewater N/PMMoV concentrations; a negative ATT  
208 value suggests that a policy was associated with a decrease in wastewater N/PMMoV  
209 concentrations.


$$210 \log_{10}(N/PMMoV) = \beta_0 + \beta_1 \times time + \beta_2 \times treated + \beta_3 \times time \times treated \text{ (Equation 1)}$$

211 We recorded the ATT and associated p value for each policy in Table 1 except for the two  
212 policies that Santa Clara County also issued (see above). For each date corresponding to a  
213 policy change, we also recorded the trend in N/PMMoV over the past 14 days and the relative  
214 level of the 7-day right-aligned moving average of N/PMMoV on that date (see Text S4 in the SI  
215 for a description of trend and level calculations).<sup>71</sup> R code for the DiD analysis is available  
216 through the Stanford Digital Repository (<https://doi.org/10.25740/ch598gf0783>).<sup>57</sup>

## 217 3.0 Results and Discussion

### 218 3.1 Correlation between wastewater concentrations of SARS- 219 CoV-2 RNA and incident COVID-19 cases

220 Between 29 July 2021 and 9 August 2023, wastewater N gene concentrations from CR2C  
221 ranged from not detected to  $2.4 \times 10^6$  gc/g (mean:  $1.3 \times 10^5$  gc/g, median:  $4.4 \times 10^4$  gc/g)  
222 (Figure 1). PMMoV-normalized wastewater concentrations ranged from not detected to  $5.0 \times 10^{-3}$   
223 (mean:  $2.4 \times 10^{-4}$ , median:  $6.4 \times 10^{-5}$ ) (Figure 1). Reported daily incident COVID-19 cases within  
224 the CR2C subwatershed ranged from 0 cases to 420 cases (mean: 52 cases, median: 15  
225 cases) (Figure 1). Over the entire analysis period (the week ending on 31 July 2021 through the  
226 week ending on 12 August 2023), weekly average wastewater SARS-CoV-2 RNA  
227 concentrations were positively and significantly correlated with weekly average incident COVID-  
228 19 cases using unnormalized N gene concentrations but not significantly when using normalized  
229 N gene concentrations (Table 2). The subgroup analyses suggest that the correlation between  
230 wastewater SARS-CoV-2 RNA concentrations and incident COVID-19 cases changed over  
231 time.



232  
233 Figure 1. (Top) N gene concentrations in gene copies per dry gram dry weight (gc/g), (middle) N/PMMoV  
234 concentrations, and (bottom) incident COVID-19 cases over time in the Codiga Resource Recovery  
235 Center (CR2C) subsewershed. Gray circles represent measurements; error bars are one standard  
236 deviation. Gray triangles indicate measurements outside of the range shown on the plot. Black lines  
237 represent weekly average values. The shaded area corresponds to the nonacademic year. The dashed  
238 lines correspond to the date the surveillance testing requirement was suspended (7 April 2022) and the  
239 date of widespread availability of self-administered COVID-19 antigen tests in the region (1 May 2022).

240 Weekly average wastewater SARS-CoV-2 RNA concentrations were positively and significantly  
241 correlated with weekly average incident COVID-19 cases during the academic year using both  
242 unnormalized and normalized N gene concentrations; this correlation was insignificant during  
243 the nonacademic portion of the year (Table 2). The decrease in students on campus and  
244 increase in nonresidential visitors during the nonacademic portion of the year may explain the

245 insignificant correlation during the nonacademic year. The COVID-19 case surveillance data  
246 only includes reported student cases residing within the CR2C subwatershed, but infected,  
247 nonresidential visitors may still contribute viral RNA to the wastewater that flows to CR2C.

248 Weekly average wastewater SARS-CoV-2 RNA concentrations were positively and significantly  
249 correlated with weekly average incident COVID-19 cases before the suspension of surveillance  
250 testing using both unnormalized and normalized N gene concentrations; this correlation was  
251 insignificant after the suspension of surveillance testing using normalized N gene concentrations  
252 only (Table 2). The required, laboratory-based surveillance testing program intended to capture  
253 both symptomatic and asymptomatic cases through routine testing. Thus, fewer asymptomatic  
254 cases may have been captured in the case data after surveillance testing was suspended which  
255 may explain the insignificant correlation after this policy change.

256 Lastly, weekly average wastewater SARS-CoV-2 RNA concentrations were positively and  
257 significantly correlated with weekly average incident COVID-19 cases before the widespread  
258 availability of self-administered antigen tests using both unnormalized and normalized N gene  
259 concentrations; this correlation was insignificant after the widespread availability of self-  
260 administered antigen tests (Table 2). Positive, laboratory-based PCR tests are reportable under  
261 state-disease reporting laws;<sup>72</sup> however, self-reporting of self-administered antigen test results  
262 is voluntary. The widespread availability of self-administered antigen tests may have contributed  
263 to underreporting of cases which may explain the insignificant correlation after the change in  
264 testing options.

265 It is not possible to deduce the main driver for the change in correlation between wastewater  
266 SARS-CoV-2 RNA concentrations and incident COVID-19 cases over time, but we suspect that  
267 the change is due to several factors including changes in routine COVID-19 surveillance testing

268 requirements, changes in test reporting, and overall decreases in test-seeking behaviors as the  
 269 pandemic continues.<sup>19,73,74</sup> Wastewater monitoring data are independent of test-seeking  
 270 behaviors or test reporting patterns so may be a less biased tool for monitoring public health,  
 271 particularly in periods characterized by low test-seeking and reporting rates.

272 Table 2. Kendall’s tau correlation between weekly average wastewater SARS-CoV-2 RNA concentrations  
 273 and incident COVID-19 cases within the Codiga Resource Recovery Center subsewershed

Analysis Group (n)	Kendall’s Tau (95% Confidence Interval)	
	N (gc/g) and Cases	N/PMMoV and Cases
Entire analysis period (n = 107)	0.30 (0.18, 0.41) *	0.15 (0.02, 0.28)
Nonacademic year (n = 27)	0.33 (0.13, 0.53)	0.11 (-0.11, 0.33)
Academic year (n = 80)	0.35 (0.21, 0.48) *	0.24 (0.10, 0.38) *
Surveillance testing required (n = 36)	0.56 (0.42, 0.70) *	0.45 (0.28, 0.63) *
Surveillance testing not required (n = 71)	0.24 (0.10, 0.39) *	0.07 (-0.09, 0.23)
Before self-administered antigen tests (n = 40)	0.58 (0.46, 0.70) *	0.46 (0.29, 0.63) *
After self-administered antigen tests (n = 67)	0.21 (0.06, 0.36)	0.05 (-0.12, 0.21)

274 n = number of weeks with a weekly average wastewater concentration and weekly average case count  
 275 gc/g = gene copies per gram  
 276 \* p < 0.05 / 14 = 0.004

### 277 3.2 Association between campus COVID-19 policies and changes 278 in wastewater concentrations of SARS-CoV-2 RNA

279 Because the reliability of campus COVID-19 case surveillance data has changed over the  
 280 course of the pandemic, we used wastewater monitoring data from CR2C to evaluate the impact  
 281 of COVID-19 policies at Stanford University using a DiD approach. Table 3 summarizes the  
 282 average treatment effect on the treated (ATT) and associated p value for each unique date

283 associated with a change in campus COVID-19 policies as estimated using Equation 1. The two  
284 policies that were also implemented by Santa Clara County were omitted from the analysis.

285 Dates associated with a significant change ( $p \leq 0.05$ ) in wastewater N/PMMoV concentrations  
286 are shaded (red if  $ATT > 0$  and blue if  $ATT < 0$ ). For all dates, the 14-day trend in N/PMMoV and  
287 the relative level of the 7-day right-aligned moving average of N/PMMoV is provided. In total, we  
288 analyzed thirteen unique dates on which at least one change in campus COVID-19 policies  
289 went into effect. Most policy change dates were not associated with a significant change in  
290 wastewater N/PMMoV concentrations at CR2C. We expected policy relaxations to be  
291 associated with no significant change in wastewater N/PMMoV concentrations because these  
292 policy types are not intended to curb virus transmission. Meanwhile, we expected policy  
293 restrictions to be associated with a significant decrease in wastewater N/PMMoV concentrations  
294 because these policy types are intended to curb virus transmission. Five policy change dates  
295 were associated with a significant change in wastewater N/PMMoV concentrations (Table 3;  
296 Figure S2 in the SI). Three of these dates corresponded to policy relaxations, one corresponded  
297 to a policy restriction, and one corresponded to both a policy relaxation and restriction, and  
298 these policies included all categories (masking, mobility, testing). A depiction of the DiD  
299 approach using the date when indoor events and gatherings were allowed to resume (28  
300 January 2022) as an example is shown in the SI (Figure S3).



301 Table 3. Difference-in-differences analysis to evaluate the association between campus COVID-19  
 302 policies and changes in wastewater N/PMMoV concentrations

<b>Date (Trend/Level)</b>	<b>Policy</b>	<b>ATT (p value)</b>
9/2/2021 (Upward/High)	Face coverings recommended outdoors in crowded settings Indoor student parties prohibited	0.72 (0.02)
9/20/2021 (None/Medium)	Surveillance testing required for faculty, staff, and postdoctoral scholars regardless of vaccination status Revised travel guidelines in effect	-0.61 (0.05)
10/8/2021 (None/Low)	Indoor student parties can resume	-0.42 (0.2)
1/3/2022 (Upward/High)	Online classes start	-0.078 (0.8)
1/5/2022 (Upward/High)	No indoor events and gatherings Outdoor-only gatherings and meetings prohibited	-0.16 (0.6)
1/18/2022 (None/High)	In-person instruction resumes	-0.00048 (1.0)
1/21/2022 (None/High)	Outdoor-only gatherings and meetings allowed again	-0.11 (0.6)
1/28/2022 (Downward/Low)	Indoor events and gatherings can resume	0.47 (0.03)
4/7/2022 (None/High)	Surveillance testing no longer required for students	-0.62 (0.02)
10/24/2022 (None/Low)	Masks no longer required in classrooms and on campus shuttles	0.11 (0.7)
1/6/2023 (Downward/Medium)	Face coverings strongly recommended indoors and in crowded outdoor settings	-0.26 (0.3)
3/24/2023 (Upward/High)	Optional, free, laboratory-based PCR testing ends for employees	0.72 (0.008)
6/18/2023 (None/Low)	Optional, free, laboratory-based PCR testing ends for students	0.37 (0.3)

303 ATT = average treatment effect on the treated

304 The policy restriction associated with a significant change in N/PMMoV concentrations  
 305 (recommending face coverings outdoors and prohibiting indoor parties on 2 September 2021)  
 306 was associated with a significant increase rather than decrease in N/PMMoV concentrations.

307 N/PMMoV concentrations were already exhibiting a significant upward trend on 2 September  
308 2021. These policy restrictions may have been triggered by a rise in infections on campus, so  
309 N/PMMoV concentrations may have continued to increase over the following 14 days as part of  
310 the natural epidemic curve.<sup>75</sup> Similarly, the significant increase in N/PMMoV concentrations  
311 associated with the ending of optional, free, laboratory-based PCR testing for employees (24  
312 March 2023) may be because N/PMMoV concentrations were already exhibiting a significant  
313 upward trend on 24 March 2023. N/PMMoV concentrations may have continued to increase  
314 over the following 14 days as part of the natural epidemic curve and not because of this policy  
315 relaxation.<sup>75</sup> The significant increase in N/PMMoV concentrations associated with allowing  
316 indoor gatherings to resume (28 January 2022) may suggest that indoor gatherings are high-risk  
317 activities for SARS-CoV-2 transmission on campus. The significant decrease in N/PMMoV  
318 concentrations associated with suspending the surveillance testing requirement for students (7  
319 April 2022) is difficult to reconcile with expectations. Given our expectation about policy  
320 relaxations, we did not expect this policy relaxation to be associated with a significant change in  
321 N/PMMoV concentrations but there are several other factors that can affect the DiD results as  
322 discussed later with limitations of the DiD design. The remaining date (20 September 2021) was  
323 associated with a significant decrease in N/PMMoV concentrations. Both a policy relaxation  
324 (revised travel guidelines) and policy restriction (surveillance testing required for all faculty, staff,  
325 and postdoctoral scholars) were implemented; it is not possible to disentangle the individual  
326 causal effects of policies implemented on the same day.

327 Because the wastewater data from CR2C and RWQCP are not truly independent—although  
328 CR2C comprises only a very small proportion of RWQCP—we also implemented the DiD  
329 analysis using wastewater data from the San José-Santa Clara Regional Wastewater Facility  
330 (RWF)<sup>76</sup> as a comparison group (Table S2 in the SI) and found similar results as provided

331 above (see SI). The similar findings using a different comparison group strengthens the  
332 credibility of our DiD analysis and affirms the plausibility of the parallel trends assumption.<sup>77</sup>

333 There are several limitations to our DiD analysis which may impact the interpretation of our  
334 results. First, policies may not be associated with immediate effects on outcomes.<sup>75</sup> The policies  
335 we considered may have been associated with long-term effects on wastewater N/PMMoV  
336 concentrations despite being associated with null short-term effects. However, we determined  
337 that the 14 days preceding and succeeding a policy was the most justified time interval for the  
338 DiD design given that the maximum incubation period for SARS-CoV-2 is 14 days and people  
339 who shed SARS-CoV-2 RNA generally do so at the start of infection.<sup>61–65</sup> When using 14 days,  
340 the pre- or post-treatment period of one policy overlapped with part of the pre- or post-treatment  
341 period of another policy for policies implemented close together which may lead to cumulative  
342 impacts on wastewater N/PMMoV concentrations that are not possible to disentangle. Second,  
343 COVID-19 vaccines—which are a highly effective pharmaceutical intervention—were widely  
344 available during our entire analysis period with vaccination rates being very high among the  
345 Stanford University and greater Santa Clara County populations.<sup>68,78</sup> The insignificant change in  
346 N/PMMoV concentrations we observed after most policy restrictions may be due to the  
347 effectiveness of vaccines and not necessarily because these policies are unimportant. Modeling  
348 studies suggest that the success of COVID-19 vaccination programs is contingent upon  
349 appropriate use of NPIs.<sup>79–82</sup> Third, there were sometimes campus announcements or national  
350 news headlines about COVID-19 preceding the implementation of policies which could impact  
351 peoples' behaviors leading up to the actual policy change date.<sup>75</sup> Peoples' knowledge about the  
352 gravity of the COVID-19 pandemic has been shown to influence the effectiveness of lockdown  
353 policies.<sup>39</sup> Lastly, the large influx of students and visitors to campus at the starts of quarters and  
354 commencements may mask the intended effects of campus policies implemented around the

355 same time. Unlike major holidays, which result in nationwide travel (i.e., to both CR2C and  
356 RWQCP), commencements and the first day of classes result in migration specifically to  
357 Stanford's campus that is unaccounted for in the DiD design. We conducted the DiD analysis for  
358 commencements and the first day of classes of each quarter (Table S2 in the SI) and only two  
359 starts of quarters were associated with a significant change in wastewater N/PMMoV  
360 concentrations at CR2C (decrease at the start of autumn 2021 and increase at the start of  
361 spring 2022).

362 Nonetheless, our analysis is highlighted by several strengths. We empirically assessed the  
363 impact of policies among a vaccinated university population. A study focused on vaccinated  
364 populations at universities in the United Kingdom concluded that mask wearing and social  
365 distancing measures were most important using a modeling approach.<sup>33</sup> Our approach using  
366 empirical data suggests that most policies were associated with insignificant impacts although  
367 gatherings may be a particularly high-risk factor for virus transmission on campus. For our  
368 empirical approach, we used longitudinal wastewater monitoring data. We first demonstrated  
369 that the correlation between wastewater SARS-CoV-2 RNA concentrations and incident COVID-  
370 19 cases at Stanford has changed over time, suggesting that wastewater monitoring data is  
371 more reliable than clinical surveillance data for use cases such as policy impact evaluation. We  
372 further considered both policy restrictions and policy relaxations during a period when COVID-  
373 19 vaccines were widely available. Previous studies that empirically assessed the impact of  
374 NPIs on health-related outcomes generally only focused on restrictions and were most  
375 commonly conducted at the start of the pandemic when economies were not fully opened and  
376 vaccines were not available. It is not only important to evaluate the implementation of policies  
377 but also whether policies are eventually relaxed appropriately, especially because the success  
378 of vaccination campaigns is influenced by NPIs.<sup>79–82</sup> Lastly, we used a quasi-experimental

379 design to statistically evaluate changes in wastewater N/PMMoV concentrations associated with  
380 policy change dates rather than simply using a qualitative or before-and-after descriptive  
381 approach. The DiD design presented herein may be adapted in the future to assess the  
382 implications of NPIs for other diseases that may be monitored in wastewater such as influenza  
383 and respiratory syncytial virus.<sup>83</sup>

## 384 4.0 Conclusions

385 We assessed the correlation between wastewater concentrations of SARS-CoV-2 RNA and  
386 incident, reported COVID-19 cases at a university and evaluated changes to this correlation  
387 over time. Consistent with other studies, we provide evidence that the correlation between  
388 wastewater SARS-CoV-2 RNA concentrations and incident COVID-19 cases has changed over  
389 time. We further investigated the use of longitudinal wastewater monitoring data for policy  
390 impact evaluation. Using a DiD approach, we observed that most dates on which changes to  
391 campus COVID-19 policies occurred were not associated with a significant change in  
392 wastewater SARS-CoV-2 RNA concentrations on campus. However, we did not expect to  
393 observe a significant change in wastewater SARS-CoV-2 RNA concentrations after all policy  
394 change dates, particularly those dates on which existing policies were phased out. The work  
395 presented herein demonstrates how longitudinal wastewater monitoring of viruses may be used  
396 for causal inference such as policy impact evaluation, especially at small geographic scales.

## 397 Supporting Information

398 Supporting Information: Supplementary figures, text, and tables, including sewershed maps and  
399 experimental details (PDF)

## 400 Acknowledgements

401 We acknowledge feedback on study design, implementation, and interpretation from James  
402 Jacobs, Julie Parsonnet, Russell Furr, Rich Wittman, Robyn Tepper, Jorge Salinas, Bonnie  
403 Maldonado, Christina Kong, and Stephanie Kalfayan. We acknowledge Palo Alto and San Jose  
404 wastewater treatment plant staff and the CR2C Student Operators team for wastewater sample  
405 collection.

## 406 Disclosures

407 Authors declare no conflicts of interest.

## 408 References

- 409 (1) U.S. Centers for Disease Control and Prevention. *Nonpharmaceutical Interventions (NPIs)*.  
410 <https://www.cdc.gov/nonpharmaceutical-interventions/index.html> (accessed 2023-07-18).
- 411 (2) Kaiser Family Foundation. *State Actions to Mitigate the Spread of COVID-19*. State Health  
412 Facts. [https://www.kff.org/other/state-indicator/state-actions-to-mitigate-the-spread-of-covid-](https://www.kff.org/other/state-indicator/state-actions-to-mitigate-the-spread-of-covid-19/)  
413 [19/](https://www.kff.org/other/state-indicator/state-actions-to-mitigate-the-spread-of-covid-19/) (accessed 2023-07-18).
- 414 (3) Qualls, N.; Levitt, A.; Kanade, N.; Wright-Jegede, N.; Wright-Jegede, S.; Biggerstaff, M.;  
415 Reed, C.; Uzicanin, A. Community Mitigation Guidelines to Prevent Pandemic Influenza —  
416 United States, 2017. *MMWR Recomm. Rep.* **2017**, 66 (No. RR-1), 1–34.  
417 <https://doi.org/10.15585/mmwr.rr6601a1>.
- 418 (4) Deb, P.; Furceri, D.; Ostry, J. D.; Tawk, N. The Economic Effects of COVID-19 Containment  
419 Measures. *Open Econ. Rev.* **2022**, 33 (1), 1–32. [https://doi.org/10.1007/s11079-021-09638-](https://doi.org/10.1007/s11079-021-09638-2)  
420 [2.](https://doi.org/10.1007/s11079-021-09638-2)

- 421 (5) Hosseinzadeh, P.; Zareipour, M.; Baljani, E.; Moradali, M. R. Social Consequences of the  
422 COVID-19 Pandemic. A Systematic Review. *Investig. Educ. En Enfermeria* **2022**, *40* (1),  
423 e10. <https://doi.org/10.17533/udea.iee.v40n1e10>.
- 424 (6) Iezadi, S.; Gholipour, K.; Azami-Aghdash, S.; Ghiasi, A.; Rezapour, A.; Pourasghari, H.;  
425 Pashazadeh, F. Effectiveness of Non-Pharmaceutical Public Health Interventions against  
426 COVID-19: A Systematic Review and Meta-Analysis. *PLoS ONE* **2021**, *16* (11), e0260371.  
427 <https://doi.org/10.1371/journal.pone.0260371>.
- 428 (7) Mendez-Brito, A.; Bcheraoui, C. E.; Pozo-Martin, F. Systematic Review of Empirical Studies  
429 Comparing the Effectiveness of Non-Pharmaceutical Interventions against COVID-19. *J.*  
430 *Infect.* **2021**, *83* (3), 281–293. <https://doi.org/10.1016/j.jinf.2021.06.018>.
- 431 (8) Poeschl, J.; Larsen, R. B. *How Do Non-Pharmaceutical Interventions Affect the Spread of*  
432 *COVID-19? A Literature Review*; Economic Memo No. 4; Danmarks Nationalbank, 2021.  
433 [https://www.nationalbanken.dk/en/news-and-knowledge/publications-and-speeches/archive-](https://www.nationalbanken.dk/en/news-and-knowledge/publications-and-speeches/archive-publications/2021/how-do-non-pharmaceutical-interventions-affect-the-spread-of-covid-19-a-literature-review)  
434 [publications/2021/how-do-non-pharmaceutical-interventions-affect-the-spread-of-covid-19-](https://www.nationalbanken.dk/en/news-and-knowledge/publications-and-speeches/archive-publications/2021/how-do-non-pharmaceutical-interventions-affect-the-spread-of-covid-19-a-literature-review)  
435 [a-literature-review](https://www.nationalbanken.dk/en/news-and-knowledge/publications-and-speeches/archive-publications/2021/how-do-non-pharmaceutical-interventions-affect-the-spread-of-covid-19-a-literature-review) (accessed 2023-07-18).
- 436 (9) Rizvi, R. F.; Craig, K. J. T.; Hekmat, R.; Reyes, F.; South, B.; Rosario, B.; Kassler, W. J.;  
437 Jackson, G. P. Effectiveness of Non-Pharmaceutical Interventions Related to Social  
438 Distancing on Respiratory Viral Infectious Disease Outcomes: A Rapid Evidence-Based  
439 Review and Meta-Analysis. *SAGE Open Med.* **2021**, *9*, 20503121211022972.  
440 <https://doi.org/10.1177/20503121211022973>.
- 441 (10) Talic, S.; Shah, S.; Wild, H.; Gasevic, D.; Maharaj, A.; Ademi, Z.; Li, X.; Xu, W.; Mesa-  
442 Eguiagaray, I.; Rostron, J.; Theodoratou, E.; Zhang, X.; Motee, A.; Liew, D.; Ilic, D.  
443 Effectiveness of Public Health Measures in Reducing the Incidence of Covid-19, SARS-  
444 CoV-2 Transmission, and Covid-19 Mortality: Systematic Review and Meta-Analysis. *The*  
445 *BMJ* **2021**, *375*, e068302. <https://doi.org/10.1136/bmj-2021-068302>.

- 446 (11) Banholzer, N.; Lison, A.; Özcelik, D.; Stadler, T.; Feuerriegel, S.; Vach, W. The  
447 Methodologies to Assess the Effectiveness of Non-Pharmaceutical Interventions during  
448 COVID-19: A Systematic Review. *Eur. J. Epidemiol.* **2022**, *37* (10), 1003–1024.  
449 <https://doi.org/10.1007/s10654-022-00908-y>.
- 450 (12) Rubin, R. COVID-19 Testing Moves Out of the Clinic and Into the Home. *JAMA* **2021**,  
451 *326* (14), 1362–1364. <https://doi.org/10.1001/jama.2021.15679>.
- 452 (13) Aktay, A.; Bavadekar, S.; Cossoul, G.; Davis, J.; Desfontaines, D.; Fabrikant, A.;  
453 Gabrilovich, E.; Gadepalli, K.; Gipson, B.; Guevara, M.; Kamath, C.; Kansal, M.; Lange, A.;  
454 Mandayam, C.; Oplinger, A.; Pluntke, C.; Roessler, T.; Schlosberg, A.; Shekel, T.; Vispute,  
455 S.; Vu, M.; Wellenius, G.; Williams, B.; Wilson, R. J. Google COVID-19 Community Mobility  
456 Reports: Anonymization Process Description (Version 1.1). arXiv November 3, 2020.  
457 <https://doi.org/10.48550/arXiv.2004.04145>.
- 458 (14) Kishore, N.; Taylor, A. R.; Jacob, P. E.; Vembar, N.; Cohen, T.; Buckee, C. O.; Menzies,  
459 N. A. Evaluating the Reliability of Mobility Metrics from Aggregated Mobile Phone Data as  
460 Proxies for SARS-CoV-2 Transmission in the USA: A Population-Based Study. *Lancet Digit.*  
461 *Health* **2022**, *4* (1), e27–e36. [https://doi.org/10.1016/S2589-7500\(21\)00214-4](https://doi.org/10.1016/S2589-7500(21)00214-4).
- 462 (15) World Health Organization. *Environmental Surveillance for SARS-COV-2 to*  
463 *Complement Public Health Surveillance: Interim Guidance*; WHO/HEP/ECH/WSH/2022.1;  
464 World Health Organization, 2022.  
465 [https://apps.who.int/iris/bitstream/handle/10665/353158/WHO-HEP-ECH-WSH-2022.1-](https://apps.who.int/iris/bitstream/handle/10665/353158/WHO-HEP-ECH-WSH-2022.1-eng.pdf?sequence=1)  
466 [eng.pdf?sequence=1](https://apps.who.int/iris/bitstream/handle/10665/353158/WHO-HEP-ECH-WSH-2022.1-eng.pdf?sequence=1) (accessed 2023-02-15).
- 467 (16) Peccia, J.; Zulli, A.; Brackney, D. E.; Grubaugh, N. D.; Kaplan, E. H.; Casanovas-  
468 Massana, A.; Ko, A. I.; Malik, A. A.; Wang, D.; Wang, M.; Warren, J. L.; Weinberger, D. M.;  
469 Arnold, W.; Omer, S. B. Measurement of SARS-CoV-2 RNA in Wastewater Tracks  
470 Community Infection Dynamics. *Nat. Biotechnol.* **2020**, *38* (10), 1164–1167.



- 471 <https://doi.org/10.1038/s41587-020-0684-z>.
- 472 (17) Graham, K. E.; Loeb, S. K.; Wolfe, M. K.; Catoe, D.; Sinnott-Armstrong, N.; Kim, S.;  
473 Yamahara, K. M.; Sassoubre, L. M.; Mendoza Grijalva, L. M.; Roldan-Hernandez, L.;  
474 Langenfeld, K.; Wigginton, K. R.; Boehm, A. B. SARS-CoV-2 RNA in Wastewater Settled  
475 Solids Is Associated with COVID-19 Cases in a Large Urban Sewershed. *Environ. Sci.*  
476 *Technol.* **2021**, *55* (1), 488–498. <https://doi.org/10.1021/acs.est.0c06191>.
- 477 (18) D’Aoust, P. M.; Mercier, E.; Montpetit, D.; Jia, J.-J.; Alexandrov, I.; Neault, N.; Baig, A.  
478 T.; Mayne, J.; Zhang, X.; Alain, T.; Langlois, M.-A.; Servos, M. R.; MacKenzie, M.; Figeys,  
479 D.; MacKenzie, A. E.; Graber, T. E.; Delatolla, R. Quantitative Analysis of SARS-CoV-2  
480 RNA from Wastewater Solids in Communities with Low COVID-19 Incidence and  
481 Prevalence. *Water Res.* **2021**, *188*, 116560. <https://doi.org/10.1016/j.watres.2020.116560>.
- 482 (19) Boehm, A. B.; Wolfe, M. K.; White, B.; Hughes, B.; Duong, D. Divergence of Wastewater  
483 SARS-CoV-2 and Reported Laboratory-Confirmed COVID-19 Incident Case Data  
484 Coincident with Wide-Spread Availability of at-Home COVID-19 Antigen Tests. *PeerJ* **2023**,  
485 *11*, e15631. <https://doi.org/10.7717/peerj.15631>.
- 486 (20) Zambrana, W.; Catoe, D.; Coffman, M. M.; Kim, S.; Anand, A.; Solis, D.; Sahoo, M. K.;  
487 Pinsky, B. A.; Bhatt, A. S.; Boehm, A. B.; Wolfe, M. K. SARS-CoV-2 RNA and N Antigen  
488 Quantification via Wastewater at the Campus Level, Building Cluster Level, and Individual-  
489 Building Level. *ACS EST Water* **2022**, *acsestwater.2c00050*.  
490 <https://doi.org/10.1021/acsestwater.2c00050>.
- 491 (21) Davó, L.; Seguí, R.; Botija, P.; Beltrán, M. J.; Albert, E.; Torres, I.; López-Fernández, P.  
492 Á.; Ortí, R.; Maestre, J. F.; Sánchez, G.; Navarro, D. Early Detection of SARS-CoV-2  
493 Infection Cases or Outbreaks at Nursing Homes by Targeted Wastewater Tracking. *Clin.*  
494 *Microbiol. Infect.* **2021**, *27* (7), 1061–1063. <https://doi.org/10.1016/j.cmi.2021.02.003>.
- 495 (22) Karthikeyan, S.; Nguyen, A.; McDonald, D.; Zong, Y.; Ronquillo, N.; Ren, J.; Zou, J.;

- 496 Farmer, S.; Humphrey, G.; Henderson, D.; Javidi, T.; Messer, K.; Anderson, C.; Schooley,  
497 R.; Martin, N. K.; Knight, R. Rapid, Large-Scale Wastewater Surveillance and Automated  
498 Reporting System Enable Early Detection of Nearly 85% of COVID-19 Cases on a  
499 University Campus. *mSystems* **2021**, 6 (4), 10.1128/msystems.00793-21.  
500 <https://doi.org/10.1128/msystems.00793-21>.
- 501 (23) Acosta, N.; Bautista, M. A.; Waddell, B. J.; McC Calder, J.; Beaudet, A. B.; Man, L.;  
502 Pradhan, P.; Sedaghat, N.; Papparis, C.; Bacanu, A.; Hollman, J.; Krusina, A.; Southern, D.  
503 A.; Williamson, T.; Li, C.; Bhatnagar, S.; Murphy, S.; Chen, J.; Kuzma, D.; Clark, R.;  
504 Meddings, J.; Hu, J.; Cabaj, J. L.; Conly, J. M.; Dai, X.; Lu, X.; Chekouo, T.; Ruecker, N. J.;  
505 Achari, G.; Ryan, M. C.; Frankowski, K.; Hubert, C. R. J.; Parkins, M. D. Longitudinal SARS-  
506 CoV-2 RNA Wastewater Monitoring across a Range of Scales Correlates with Total and  
507 Regional COVID-19 Burden in a Well-Defined Urban Population. *Water Res.* **2022**, 220,  
508 118611. <https://doi.org/10.1016/j.watres.2022.118611>.
- 509 (24) Greenwald, H. D.; Kennedy, L. C.; Hinkle, A.; Whitney, O. N.; Fan, V. B.; Crits-Christoph,  
510 A.; Harris-Lovett, S.; Flamholz, A. I.; Al-Shayeb, B.; Liao, L. D.; Beyers, M.; Brown, D.;  
511 Chakrabarti, A. R.; Dow, J.; Frost, D.; Koekemoer, M.; Lynch, C.; Sarkar, P.; White, E.;  
512 Kantor, R.; Nelson, K. L. Tools for Interpretation of Wastewater SARS-CoV-2 Temporal and  
513 Spatial Trends Demonstrated with Data Collected in the San Francisco Bay Area. *Water*  
514 *Res. X* **2021**, 12, 100111. <https://doi.org/10.1016/j.wroa.2021.100111>.
- 515 (25) Crowe, J.; Schnaubelt, A. T.; SchmidtBonne, S.; Angell, K.; Bai, J.; Eske, T.; Nicklin, M.;  
516 Pratt, C.; White, B.; Crotts-Hannibal, B.; Staffend, N.; Herrera, V.; Cobb, J.; Conner, J.;  
517 Carstens, J.; Tempero, J.; Bouda, L.; Ray, M.; Lawler, J. V.; Campbell, W. S.; Lowe, J.-M.;  
518 Santarpia, J.; Bartelt-Hunt, S.; Wiley, M.; Brett-Major, D.; Logan, C.; Broadhurst, M. J.  
519 Assessment of a Program for SARS-CoV-2 Screening and Environmental Monitoring in an  
520 Urban Public School District. *JAMA Netw. Open* **2021**, 4 (9), e2126447.

- 521 <https://doi.org/10.1001/jamanetworkopen.2021.26447>.
- 522 (26) Betancourt, W. Q.; Schmitz, B. W.; Innes, G. K.; Prasek, S. M.; Pogreba Brown, K. M.;
- 523 Stark, E. R.; Foster, A. R.; Sprissler, R. S.; Harris, D. T.; Sherchan, S. P.; Gerba, C. P.;
- 524 Pepper, I. L. COVID-19 Containment on a College Campus via Wastewater-Based
- 525 Epidemiology, Targeted Clinical Testing and an Intervention. *Sci. Total Environ.* **2021**, 779,
- 526 146408. <https://doi.org/10.1016/j.scitotenv.2021.146408>.
- 527 (27) Gibas, C.; Lambirth, K.; Mittal, N.; Juel, M. A. I.; Barua, V. B.; Roppolo Brazell, L.;
- 528 Hinton, K.; Lontai, J.; Stark, N.; Young, I.; Quach, C.; Russ, M.; Kauer, J.; Nicolosi, B.;
- 529 Chen, D.; Akella, S.; Tang, W.; Schlueter, J.; Munir, M. Implementing Building-Level SARS-
- 530 CoV-2 Wastewater Surveillance on a University Campus. *Sci. Total Environ.* **2021**, 782,
- 531 146749. <https://doi.org/10.1016/j.scitotenv.2021.146749>.
- 532 (28) Scott, L. C.; Aubee, A.; Babahaji, L.; Vigil, K.; Tims, S.; Aw, T. G. Targeted Wastewater
- 533 Surveillance of SARS-CoV-2 on a University Campus for COVID-19 Outbreak Detection and
- 534 Mitigation. *Environ. Res.* **2021**, 200, 111374. <https://doi.org/10.1016/j.envres.2021.111374>.
- 535 (29) Colosi, L. M.; Barry, K. E.; Kotay, S. M.; Porter, M. D.; Poulter, M. D.; Ratliff, C.;
- 536 Simmons, W.; Steinberg, L. I.; Wilson, D. D.; Morse, R.; Zmick, P.; Mathers, A. J.
- 537 Development of Wastewater Pooled Surveillance of Severe Acute Respiratory Syndrome
- 538 Coronavirus 2 (SARS-CoV-2) from Congregate Living Settings. *Appl. Environ. Microbiol.*
- 539 **2021**, 87 (13), e00433-21. <https://doi.org/10.1128/AEM.00433-21>.
- 540 (30) Wong, J. C. C.; Tan, J.; Lim, Y. X.; Arivalan, S.; Hapuarachchi, H. C.; Mailepessov, D.;
- 541 Griffiths, J.; Jayarajah, P.; Setoh, Y. X.; Tien, W. P.; Low, S. L.; Koo, C.; Yenamandra, S. P.;
- 542 Kong, M.; Lee, V. J. M.; Ng, L. C. Non-Intrusive Wastewater Surveillance for Monitoring of a
- 543 Residential Building for COVID-19 Cases. *Sci. Total Environ.* **2021**, 786, 147419.
- 544 <https://doi.org/10.1016/j.scitotenv.2021.147419>.
- 545 (31) Barrios, R. E.; Lim, C.; Kelley, M. S.; Li, X. SARS-CoV-2 Concentrations in a

546 Wastewater Collection System Indicated Potential COVID-19 Hotspots at the Zip Code  
547 Level. *Sci. Total Environ.* **2021**, 800, 149480.  
548 <https://doi.org/10.1016/j.scitotenv.2021.149480>.

549 (32) Rubio-Acero, R.; Beyerl, J.; Muenchhoff, M.; Roth, M. S.; Castelletti, N.; Paunovic, I.;  
550 Radon, K.; Springer, B.; Nagel, C.; Boehm, B.; Böhmer, M. M.; Graf, A.; Blum, H.; Krebs, S.;  
551 Keppler, O. T.; Osterman, A.; Khan, Z. N.; Hoelscher, M.; Wieser, A.; Emad, A.; Jared, A.;  
552 Abhishek, B.; Maxilmilian, B.; Marc, B.; Franziska, B.; Olimbek, B.; Jessica, B.; Patrick, B.;  
553 Rebecca, B.; Isabel, B.; Jan, B.; Friedrich, C.; Noemi, C.; Josephine, C.; Lorenzo, C.; Alina,  
554 C.; Flora, D.; Diefenbach Maximilian, N.; Jana, D.; Gerhard, D.; Jürgen, D.; Ute, E.; Judith,  
555 E.; Tabea, E.; Philine, F.; Manuela, F.; Volker, F.; Felix, F.; Turid, F.; Jonathan, F.; Günter,  
556 F.; Christiane, F.; Mercè, G.; Otto, G.; Christof, G.; Leonard, G.; Kristina, G.; Philipp, G.;  
557 Elias, G.; Michelle, G. N. J.; Maria, G. E.; Pablo, G.; Anslem, H.; Marlene, H.; Lena, H.; Jan,  
558 H.; Alejandra, H.; Leah, H.; Christian, H.; Tim, H.; Michael, H.; Sacha, H.; Kristina, H.;  
559 Christian, J.; Ursula, K.; Antonia, K.; Zohaib, K.; Johanna, K.; Inge, K.; Arne, K.; Magdalena,  
560 L.; Clemens, L.; Silvan, L.; Michael, L.; Ronan, L. G.; Reiner, L.; Leopold, L.; Xhovana, L.;  
561 Fabian, L.; Sophie, N. A.; Petra, M.; Alisa, M.; Rebecca, M.; Dafni, M.; Hannah, M.;  
562 Katharina, M.; Laura, O.; Ivana, P.; Michael, P.; Claire, P.; Michel, P.; Michael, P.; Stephan,  
563 P.; Kerstin, P.; Peter, P.; Katja, R.; Elba, R.; Jakob, R.; Friedrich, R.; Camilla, R.; Raquel,  
564 R.-A.; Viktoria, R.; Elmar, S.; Nicole, S.; Yannik, S.; Benedikt, S.; Lara, S.; Mirjam, S.; Lars,  
565 S.; Alba, S.; Peter, S.; Kathrin, S.; Jeni, T.; Fabian, T.; Verena, T.; Sophie, T.; Vincent, V.;  
566 Emilia, V. L.; Jonathan, V. L.; Julia, W.; Claudia, W.; Andreas, W.; Simon, W.; Roman, W.;  
567 Julia, W.; Tobias, W.; Sabine, Z.; Eleftheria, Z.; Anna, Z.; Thorbjörn, Z. Spatially Resolved  
568 Qualified Sewage Spot Sampling to Track SARS-CoV-2 Dynamics in Munich - One Year of  
569 Experience. *Sci. Total Environ.* **2021**, 797, 149031.  
570 <https://doi.org/10.1016/j.scitotenv.2021.149031>.

- 571 (33) Niu, Z.; Scarciotti, G. Ranking the Effectiveness of Non-Pharmaceutical Interventions to  
572 Counter COVID-19 in UK Universities with Vaccinated Population. *Sci. Rep.* **2022**, *12* (1),  
573 13039. <https://doi.org/10.1038/s41598-022-16532-5>.
- 574 (34) Bärnighausen, T.; Tugwell, P.; Røttingen, J.-A.; Shemilt, I.; Rockers, P.; Geldsetzer, P.;  
575 Lavis, J.; Grimshaw, J.; Daniels, K.; Brown, A.; Bor, J.; Tanner, J.; Rashidian, A.; Barreto,  
576 M.; Vollmer, S.; Atun, R. Quasi-Experimental Study Designs Series—Paper 4: Uses and  
577 Value. *J. Clin. Epidemiol.* **2017**, *89*, 21–29. <https://doi.org/10.1016/j.jclinepi.2017.03.012>.
- 578 (35) Lechner, M. The Estimation of Causal Effects by Difference-in-Difference Methods.  
579 *Found. Trends® Econom.* **2011**, *4* (3), 165–224. <https://doi.org/10.1561/08000000014>.
- 580 (36) Gertler, P. J.; Martinez, S.; Premand, P.; Rawlings, L. B.; Vermeersch, C. M. J. *Impact*  
581 *Evaluation in Practice, Second Edition*; Washington, DC: Inter-American Development Bank  
582 and World Bank, 2016. <https://doi.org/10.1596/978-1-4648-0779-4>.
- 583 (37) Fang, H.; Wang, L.; Yang. Human Mobility Restrictions and the Spread of the Novel  
584 Coronavirus (2019-NCoV) in China. National Bureau of Economic Research March 2020.  
585 <https://doi.org/10.3386/w26906>.
- 586 (38) Friedson, A. I.; McNichols, D.; Sabia, J. J.; Dave, D. Did California’s Shelter-in-Place  
587 Order Work? Early Coronavirus-Related Public Health Effects. National Bureau of Economic  
588 Research April 2020. <https://doi.org/10.3386/w26992>.
- 589 (39) Loiacono, L.; Puglisi, R.; Rizzo, L.; Secomandi, R. Pandemic Knowledge and Regulation  
590 Effectiveness: Evidence from COVID-19. *J. Comp. Econ.* **2022**, *50* (3), 768–783.  
591 <https://doi.org/10.1016/j.jce.2022.02.004>.
- 592 (40) Berry, C. R.; Fowler, A.; Glazer, T.; Handel-Meyer, S.; MacMillen, A. Evaluating the  
593 Effects of Shelter-in-Place Policies during the COVID-19 Pandemic. *Proc. Natl. Acad. Sci.*  
594 **2021**, *118* (15), e2019706118. <https://doi.org/10.1073/pnas.2019706118>.
- 595 (41) Courtemanche, C.; Garuccio, J.; Le, A.; Pinkston, J.; Yelowitz, A. Strong Social

- 596 Distancing Measures In The United States Reduced The COVID-19 Growth Rate. *Health*  
597 *Aff. (Millwood)* **2020**, 39 (7), 1237–1246. <https://doi.org/10.1377/hlthaff.2020.00608>.
- 598 (42) Dave, D.; Friedson, A.; Matsuzawa, K.; Sabia, J. J.; Safford, S. JUE Insight: Were Urban  
599 Cowboys Enough to Control COVID-19? Local Shelter-in-Place Orders and Coronavirus  
600 Case Growth. *J. Urban Econ.* **2022**, 127, 103294. <https://doi.org/10.1016/j.jue.2020.103294>.
- 601 (43) Dave, D. M.; Friedson, A. I.; Matsuzawa, K.; McNichols, D.; Sabia, J. J. Are the Effects  
602 of Adoption and Termination of Shelter-in-Place Orders Symmetric? Evidence from a  
603 Natural Experiment. National Bureau of Economic Research June 2020.  
604 <https://doi.org/10.3386/w27322>.
- 605 (44) Juranek, S.; Zoutman, F. T. The Effect of Non-Pharmaceutical Interventions on the  
606 Demand for Health Care and on Mortality: Evidence from COVID-19 in Scandinavia. *J.*  
607 *Popul. Econ.* **2021**, 34 (4), 1299–1320. <https://doi.org/10.1007/s00148-021-00868-9>.
- 608 (45) Stanford University. *Codiga Resource Recovery Center at Stanford*. Stanford  
609 Engineering. <https://cr2c.stanford.edu/> (accessed 2023-02-24).
- 610 (46) Stanford University. *Wastewater Analysis*. Stanford COVID-19 Health Alerts.  
611 <https://healthalerts.stanford.edu/covid-19/wastewater-dashboard/> (accessed 2023-03-17).
- 612 (47) City of Palo Alto. *Regional Water Quality Control Plant*. [cleanbay.org](https://cleanbay.org).  
613 <https://cleanbay.org/our-programs/regional-water-quality-control-plant/> (accessed 2023-02-  
614 24).
- 615 (48) Topol, A.; Wolfe, M.; White, B.; Wigginton, K.; Boehm, A. B. *High Throughput pre-*  
616 *analytical processing of wastewater settled solids for SARS-CoV-2 RNA analyses V.2*.  
617 [protocols.io](https://dx.doi.org/10.17504/protocols.io.b2kmqcu6). <https://dx.doi.org/10.17504/protocols.io.b2kmqcu6>.
- 618 (49) Topol, A.; Wolfe, M.; White, B.; Wigginton, K.; Boehm, A. B. *High Throughput SARS-*  
619 *COV-2, PMMOV, and BCoV quantification in settled solids using digital RT-PCR V.5*.  
620 [protocols.io](https://dx.doi.org/10.17504/protocols.io.e6nvw5orwvmk/v5). [dx.doi.org/10.17504/protocols.io.e6nvw5orwvmk/v5](https://dx.doi.org/10.17504/protocols.io.e6nvw5orwvmk/v5).

- 621 (50) Topol, A.; Wolfe, M.; Wigginton, K.; White, B.; Boehm, A. B. *High Throughput RNA*  
622 *Extraction and PCR Inhibitor Removal of Settled Solids for Wastewater Surveillance of*  
623 *SARS-CoV-2 RNA V.2.* protocols.io. <https://dx.doi.org/10.17504/protocols.io.b2mkqc4w>.
- 624 (51) Wolfe, M. K.; Topol, A.; Knudson, A.; Simpson, A.; White, B.; Vugia, D. J.; Yu, A. T.; Li,  
625 L.; Balliet, M.; Stoddard, P.; Han, G. S.; Wigginton, K. R.; Boehm, A. B. High-Frequency,  
626 High-Throughput Quantification of SARS-CoV-2 RNA in Wastewater Settled Solids at Eight  
627 Publicly Owned Treatment Works in Northern California Shows Strong Association with  
628 COVID-19 Incidence. *mSystems* **2021**, 6 (5), e00829-21.  
629 <https://doi.org/10.1128/msystems.00829-21>.
- 630 (52) Boehm, A. B.; Wolfe, M. K.; Wigginton, K. R.; Bidwell, A.; White, B. J.; Hughes, B.;  
631 Duong, D.; Chan-Herur, V.; Bischel, H. N.; Naughton, C. C. Human Viral Nucleic Acids  
632 Concentrations in Wastewater Solids from Central and Coastal California USA. *Sci. Data*  
633 **2023**, 10 (1), 396. <https://doi.org/10.1038/s41597-023-02297-7>.
- 634 (53) Huisman, J. S.; Scire, J.; Caduff, L.; Fernandez, -Cassi Xavier; Ganesanandamoorthy,  
635 P.; Kull, A.; Scheidegger, A.; Stachler, E.; Boehm, A. B.; Hughes, B.; Knudson, A.; Topol,  
636 A.; Wigginton, K. R.; Wolfe, M. K.; Kohn, T.; Ort, C.; Stadler, T.; Julian, T. R. Wastewater-  
637 Based Estimation of the Effective Reproductive Number of SARS-CoV-2. *Environ. Health*  
638 *Perspect.* 130 (5), 057011. <https://doi.org/10.1289/EHP10050>.
- 639 (54) Kitajima, M.; Sassi, H. P.; Torrey, J. R. Pepper Mild Mottle Virus as a Water Quality  
640 Indicator. *Npj Clean Water* **2018**, 1 (1), 1–9. <https://doi.org/10.1038/s41545-018-0019-5>.
- 641 (55) Wolfe, M. K.; Archana, A.; Catoe, D.; Coffman, M. M.; Dorevich, S.; Graham, K. E.; Kim,  
642 S.; Grijalva, L. M.; Roldan-Hernandez, L.; Silverman, A. I.; Sinnott-Armstrong, N.; Vugia, D.  
643 J.; Yu, A. T.; Zambrana, W.; Wigginton, K. R.; Boehm, A. B. Scaling of SARS-CoV-2 RNA in  
644 Settled Solids from Multiple Wastewater Treatment Plants to Compare Incidence Rates of  
645 Laboratory-Confirmed COVID-19 in Their Sewersheds. *Environ. Sci. Technol. Lett.* **2021**, 8



- 646 (5), 398–404. <https://doi.org/10.1021/acs.estlett.1c00184>.
- 647 (56) Boehm, A.; Wolfe, M.; Wigginton, K.; Bidwell, A.; White, B.; Duong, D.; Hughes, B.;  
648 Chan-Herur, V.; Naughton, C.; Bischel, H. N. *Human viral nucleic acids concentrations in*  
649 *wastewater solids from Central and Coastal California, USA*. Stanford Digital Repository.  
650 <https://purl.stanford.edu/cx529np1130> (accessed 2023-09-12).
- 651 (57) Chan, E.; Bidwell, A.; Li, Z.; Tilmans, S.; Boehm, A. *Data and R code for policy impact*  
652 *evaluation using wastewater SARS-CoV-2 RNA concentrations paper*. Stanford Digital  
653 Repository. <https://purl.stanford.edu/ch598gf0783>.
- 654 (58) Stanford University. *COVID-19 resources for the Stanford community*. Stanford COVID-  
655 19 Health Alerts. <https://healthalerts.stanford.edu/covid-19> (accessed 2023-02-24).
- 656 (59) Signorell, A.; Aho, K.; Alfons, A.; Anderegg, N.; Aragon, T.; Arachchige, C.; Arppe, A.;  
657 Baddeley, A.; Barton, K.; Bolker, B.; Borchers, H. W.; Caeiro, F.; Champely, S.; Chessel, D.;  
658 Chhay, L.; Cooper, N.; Cummins, C.; Dewey, M.; Doran, H. C.; Dray, S.; Dupont, C.;  
659 Eddelbuettel, D.; Ekstrom, C.; Eloff, M.; Enos, J.; Farebrother, R. W.; Fox, J.; Francois, R.;  
660 Friendly, M.; Galili, T.; Gamer, M.; Gastwirth, J. L.; Gegzna, V.; Gel, Y. R.; Graber, S.;  
661 Gross, J.; Grothendieck, G.; Jr, F. E. H.; Heiberger, R.; Hoehle, M.; Hoffmann, C. W.;  
662 Hojsgaard, S.; Hothorn, T.; Huerzeler, M.; Hui, W. W.; Hurd, P.; Hyndman, R. J.; Jackson,  
663 C.; Kohl, M.; Korpela, M.; Kuhn, M.; Labes, D.; Leisch, F.; Lemon, J.; Li, D.; Maechler, M.;  
664 Magnusson, A.; Mainwaring, B.; Malter, D.; Marsaglia, G.; Marsaglia, J.; Matei, A.; Meyer,  
665 D.; Miao, W.; Millo, G.; Min, Y.; Mitchell, D.; Mueller, F.; Naepflin, M.; Navarro, D.; Nilsson,  
666 H.; Nordhausen, K.; Ogle, D.; Ooi, H.; Parsons, N.; Pavoine, S.; Plate, T.; Prendergast, L.;  
667 Rapold, R.; Reville, W.; Rinker, T.; Ripley, B. D.; Rodriguez, C.; Russell, N.; Sabbe, N.;  
668 Scherer, R.; Seshan, V. E.; Smithson, M.; Snow, G.; Soetaert, K.; Stahel, W. A.;  
669 Stephenson, A.; Stevenson, M.; Stubner, R.; Templ, M.; Lang, D. T.; Therneau, T.; Tille, Y.;  
670 Torgo, L.; Trapletti, A.; Ulrich, J.; Ushey, K.; VanDerWal, J.; Venables, B.; Verzani, J.;




- 671 Iglesias, P. J. V.; Warnes, G. R.; Wellek, S.; Wickham, H.; Wilcox, R. R.; Wolf, P.;
- 672 Wollschlaeger, D.; Wood, J.; Wu, Y.; Yee, T.; Zeileis, A. DescTools: Tools for Descriptive
- 673 Statistics, 2023. <https://cran.r-project.org/web/packages/DescTools/index.html> (accessed
- 674 2023-08-03).
- 675 (60) Stanford University. *Academic Dates*. Stanford Student Services.
- 676 <https://studentservices.stanford.edu/calendar/academic-dates> (accessed 2023-02-24).
- 677 (61) Lauer, S. A.; Grantz, K. H.; Bi, Q.; Jones, F. K.; Zheng, Q.; Meredith, H. R.; Azman, A.
- 678 S.; Reich, N. G.; Lessler, J. The Incubation Period of Coronavirus Disease 2019 (COVID-
- 679 19) From Publicly Reported Confirmed Cases: Estimation and Application. *Ann. Intern. Med.*
- 680 **2020**, *172* (9), 577–582. <https://doi.org/10.7326/M20-0504>.
- 681 (62) U.S. Centers for Disease Control and Prevention. *Symptoms of COVID-19*.
- 682 <https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html> (accessed
- 683 2023-02-22).
- 684 (63) Arts, P. J.; Kelly, J. D.; Midgley, C. M.; Anglin, K.; Lu, S.; Abedi, G. R.; Andino, R.;
- 685 Bakker, K. M.; Banman, B.; Boehm, A. B.; Briggs-Hagen, M.; Brouwer, A. F.; Davidson, M.
- 686 C.; Eisenberg, M. C.; Garcia-Knight, M.; Knight, S.; Peluso, M. J.; Pineda-Ramirez, J.; Diaz
- 687 Sanchez, R.; Saydah, S.; Tassetto, M.; Martin, J. N.; Wigginton, K. R. Longitudinal and
- 688 Quantitative Fecal Shedding Dynamics of SARS-CoV-2, Pepper Mild Mottle Virus, and
- 689 CrAssphage. *mSphere* **2023**, *0* (0), e00132-23. <https://doi.org/10.1128/msphere.00132-23>.
- 690 (64) Wölfel, R.; Corman, V. M.; Guggemos, W.; Seilmaier, M.; Zange, S.; Müller, M. A.;
- 691 Niemeyer, D.; Jones, T. C.; Vollmar, P.; Rothe, C.; Hoelscher, M.; Bleicker, T.; Brünink, S.;
- 692 Schneider, J.; Ehmann, R.; Zwirgmaier, K.; Drosten, C.; Wendtner, C. Virological
- 693 Assessment of Hospitalized Patients with COVID-2019. *Nature* **2020**, *581* (7809), 465–469.
- 694 <https://doi.org/10.1038/s41586-020-2196-x>.
- 695 (65) Natarajan, A.; Zlitni, S.; Brooks, E. F.; Vance, S. E.; Dahlen, A.; Hedlin, H.; Park, R. M.;

- 696 Han, A.; Schmidtke, D. T.; Verma, R.; Jacobson, K. B.; Parsonnet, J.; Bonilla, H. F.; Singh,  
697 U.; Pinsky, B. A.; Andrews, J. R.; Jagannathan, P.; Bhatt, A. S. Gastrointestinal Symptoms  
698 and Fecal Shedding of SARS-CoV-2 RNA Suggest Prolonged Gastrointestinal Infection.  
699 *Med N. Y. N* **2022**, 3 (6), 371-387.e9. <https://doi.org/10.1016/j.medj.2022.04.001>.
- 700 (66) County of Santa Clara. *Success in Vaccinating Most County Residents and Low COVID-*  
701 *19 Case Rates Allow Health Officer to Adopt New, More Focused Local Order*. Santa Clara  
702 County Public Health. [https://covid19.sccgov.org/news-releases/pr-05-18-2021-scc-adopts-](https://covid19.sccgov.org/news-releases/pr-05-18-2021-scc-adopts-more-focused-local-health-order)  
703 [more-focused-local-health-order](https://covid19.sccgov.org/news-releases/pr-05-18-2021-scc-adopts-more-focused-local-health-order) (accessed 2023-08-03).
- 704 (67) California Department of Public Health. *Blueprint for a Safer Economy*. California  
705 Department of Public Health. [https://www.cdph.ca.gov/Programs/CID/DCDC/Pages/COVID-](https://www.cdph.ca.gov/Programs/CID/DCDC/Pages/COVID-19/COVID19CountyMonitoringOverview.aspx)  
706 [19/COVID19CountyMonitoringOverview.aspx](https://www.cdph.ca.gov/Programs/CID/DCDC/Pages/COVID-19/COVID19CountyMonitoringOverview.aspx) (accessed 2023-08-03).
- 707 (68) County of Santa Clara. *Bay Area Health Officials Urge Immediate Vaccination and Issue*  
708 *Orders Requiring Use of Face Coverings Indoors to Prevent the Spread of COVID-19 -*  
709 *Emergency Operations Center - County of Santa Clara*. Santa Clara County Public Health.  
710 [https://covid19.sccgov.org/news-releases/pr-08-02-2021-health-officials-urge-immediate-](https://covid19.sccgov.org/news-releases/pr-08-02-2021-health-officials-urge-immediate-vaccination-and-require-face-covering-indoors)  
711 [vaccination-and-require-face-covering-indoors](https://covid19.sccgov.org/news-releases/pr-08-02-2021-health-officials-urge-immediate-vaccination-and-require-face-covering-indoors) (accessed 2023-08-03).
- 712 (69) County of Santa Clara. *County of Santa Clara Universal Indoor Mask Requirement to*  
713 *Transition to a Recommendation March 2*. Santa Clara County Public Health.  
714 [https://covid19.sccgov.org/news-releases/pr-03-01-2022-indoor-mask-requirement-](https://covid19.sccgov.org/news-releases/pr-03-01-2022-indoor-mask-requirement-transitions-to-recommendation)  
715 [transitions-to-recommendation](https://covid19.sccgov.org/news-releases/pr-03-01-2022-indoor-mask-requirement-transitions-to-recommendation) (accessed 2023-08-03).
- 716 (70) Craig, P.; Katikireddi, S. V.; Leyland, A.; Popham, F. Natural Experiments: An Overview  
717 of Methods, Approaches, and Contributions to Public Health Intervention Research. *Annu.*  
718 *Rev. Public Health* **2017**, 38 (1), 39–56. [https://doi.org/10.1146/annurev-publhealth-031816-](https://doi.org/10.1146/annurev-publhealth-031816-044327)  
719 [044327](https://doi.org/10.1146/annurev-publhealth-031816-044327).
- 720 (71) Chan, E. M. G.; Kennedy, L. C.; Wolfe, M. K.; Boehm, A. B. Identifying Trends in SARS-

- 721 CoV-2 RNA in Wastewater to Infer Changing COVID-19 Incidence: Effect of Sampling  
722 Frequency. *PLOS Water* **2023**, 2 (4), e0000088.  
723 <https://doi.org/10.1371/journal.pwat.0000088>.
- 724 (72) U.S. Centers for Disease Control and Prevention. *What is Case Surveillance?*  
725 <https://www.cdc.gov/nndss/about/index.html> (accessed 2023-08-31).
- 726 (73) Kadonsky, K. F.; Naughton, C. C.; Susa, M.; Olson, R.; Singh, G. L.; Daza-Torres, M. L.;  
727 Montesinos-López, J. C.; Garcia, Y. E.; Gafurova, M.; Gushgari, A.; Cosgrove, J.; White, B.  
728 J.; Boehm, A. B.; Wolfe, M. K.; Nuño, M.; Bichel, H. N. Expansion of Wastewater-Based  
729 Disease Surveillance to Improve Health Equity in California’s Central Valley: Sequential  
730 Shifts in Case-to-Wastewater and Hospitalization-to-Wastewater Ratios. *Front. Public*  
731 *Health* **2023**, 11. <https://doi.org/10.3389/fpubh.2023.1141097>.
- 732 (74) Varkila, M. R. J.; Montez-Rath, M. E.; Salomon, J. A.; Yu, X.; Block, G. A.; Owens, D. K.;  
733 Chertow, G. M.; Parsonnet, J.; Anand, S. Use of Wastewater Metrics to Track COVID-19 in  
734 the US. *JAMA Netw. Open* **2023**, 6 (7), e2325591.  
735 <https://doi.org/10.1001/jamanetworkopen.2023.25591>.
- 736 (75) Goodman-Bacon, A.; Marcus, J. Using Difference-in-Differences to Identify Causal  
737 Effects of COVID-19 Policies. *Surv. Res. Methods* **2020**, 14 (2), 153–158.  
738 <https://doi.org/10.18148/srm/2020.v14i2.7723>.
- 739 (76) *San José-Santa Clara Regional Wastewater Facility*. City of San Jose.  
740 [https://www.sanjoseca.gov/your-government/environment/water-utilities/regional-](https://www.sanjoseca.gov/your-government/environment/water-utilities/regional-wastewater-facility)  
741 [wastewater-facility](https://www.sanjoseca.gov/your-government/environment/water-utilities/regional-wastewater-facility) (accessed 2022-06-16).
- 742 (77) Bärnighausen, T.; Oldenburg, C.; Tugwell, P.; Bommer, C.; Ebert, C.; Barreto, M.;  
743 Djimeu, E.; Haber, N.; Waddington, H.; Rockers, P.; Sianesi, B.; Bor, J.; Fink, G.; Valentine,  
744 J.; Tanner, J.; Stanley, T.; Sierra, E.; Tchetgen, E. T.; Atun, R.; Vollmer, S. Quasi-  
745 Experimental Study Designs Series—Paper 7: Assessing the Assumptions. *J. Clin.*

- 746 *Epidemiol.* **2017**, 89, 53–66. <https://doi.org/10.1016/j.jclinepi.2017.02.017>.
- 747 (78) Stanford University. *Update for Stanford community on unvaccinated employee testing*  
748 *and face coverings*. Stanford COVID-19 Health Alerts.  
749 [https://healthalerts.stanford.edu/covid-19/2021/07/28/update-for-stanford-community-on-](https://healthalerts.stanford.edu/covid-19/2021/07/28/update-for-stanford-community-on-unvaccinated-employee-testing-and-face-coverings/)  
750 [unvaccinated-employee-testing-and-face-coverings/](https://healthalerts.stanford.edu/covid-19/2021/07/28/update-for-stanford-community-on-unvaccinated-employee-testing-and-face-coverings/) (accessed 2023-08-22).
- 751 (79) Althobaity, Y.; Wu, J.; Tildesley, M. J. Non-Pharmaceutical Interventions and Their  
752 Relevance in the COVID-19 Vaccine Rollout in Saudi Arabia and Arab Gulf Countries.  
753 *Infect. Dis. Model.* **2022**, 7 (3), 545–560. <https://doi.org/10.1016/j.idm.2022.08.005>.
- 754 (80) Li, H.; Wang, L.; Zhang, M.; Lu, Y.; Wang, W. Effects of Vaccination and Non-  
755 Pharmaceutical Interventions and Their Lag Times on the COVID-19 Pandemic:  
756 Comparison of Eight Countries. *PLoS Negl. Trop. Dis.* **2022**, 16 (1), e0010101.  
757 <https://doi.org/10.1371/journal.pntd.0010101>.
- 758 (81) Moore, S.; Hill, E. M.; Tildesley, M. J.; Dyson, L.; Keeling, M. J. Vaccination and Non-  
759 Pharmaceutical Interventions for COVID-19: A Mathematical Modelling Study. *Lancet Infect.*  
760 *Dis.* **2021**, 21 (6), 793–802. [https://doi.org/10.1016/S1473-3099\(21\)00143-2](https://doi.org/10.1016/S1473-3099(21)00143-2).
- 761 (82) Patel, M. D.; Rosenstrom, E.; Ivy, J. S.; Mayorga, M. E.; Keskinocak, P.; Boyce, R. M.;  
762 Hassmiller Lich, K.; Smith, R. L., III; Johnson, K. T.; Delamater, P. L.; Swann, J. L.  
763 Association of Simulated COVID-19 Vaccination and Nonpharmaceutical Interventions With  
764 Infections, Hospitalizations, and Mortality. *JAMA Netw. Open* **2021**, 4 (6), e2110782.  
765 <https://doi.org/10.1001/jamanetworkopen.2021.10782>.
- 766 (83) Boehm, A. B.; Hughes, B.; Duong, D.; Chan-Herur, V.; Buchman, A.; Wolfe, M. K.;  
767 White, B. J. Wastewater Concentrations of Human Influenza, Metapneumovirus,  
768 Parainfluenza, Respiratory Syncytial Virus, Rhinovirus, and Seasonal Coronavirus Nucleic-  
769 Acids during the COVID-19 Pandemic: A Surveillance Study. *Lancet Microbe* **2023**, 4 (5),  
770 e340–e348. [https://doi.org/10.1016/S2666-5247\(22\)00386-X](https://doi.org/10.1016/S2666-5247(22)00386-X).

771 For Table of Contents Only



772